Arcus reports Phase I safety data for cancer candidate AB928

Arcus Biosciences Inc. (NYSE:RCUS) reported data from 85 healthy volunteers in a Phase I trial showing that

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE